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Abstract: Peptide-based small molecule drug conjugates for targeted tumor therapy are currently in
the focus of intensive research. Anthracyclines, like daunomycin, are commonly used anticancer drug
molecules and are also often applied in peptide-drug conjugates. However, lability of the O-glycosidic
bond during electrospray ionization mass spectrometric analysis hinders the analytical characterization
of the constructs. “Overprotonation” can occur if daunomycin is linked to positively charged peptide
carriers, like tuftsin derivatives. In these molecules, the high number of positive charges enhances
the in-source fragmentation significantly, leading to complex mass spectra composed of mainly
fragment ions. Therefore, we investigated different novel tuftsin-daunomycin conjugates to find
an appropriate condition for mass spectrometric detection. Our results showed that shifting the charge
states to lower charges helped to keep ions intact. In this way, a clear spectrum could be obtained
containing intact protonated molecules only. Shifting of the protonation states to lower charges
could be achieved with the use of appropriate neutral volatile buffers and with tuning the ion
source parameters.
Keywords: bioconjugates; peptides; anthracyclines; mass spectrometry; electrospray ionization;
fragmentation
1. Introduction
Daunomycin is a commonly used drug for cancer therapy, which is applied, especially in
leukemia [1]. It belongs to the family of anthracycline antibiotics that can bind to the DNA in the nucleus
and can inhibit the topoisomerase IIα enzyme [1,2]. The molecule consists of a tetracyclic quinoid
aglycone part and an aminoglycoside sugar moiety (daunosamine), attached through an O-glycosidic
bond to the aglycone part. Unfortunately, the use of daunomycin in clinical treatments is limited
by severe side-effects, for example, cardiotoxicity. To overcome clinical drawbacks, such as the lack
of selectivity, the fast elimination from the blood circulation, as well as toxicity, peptide-based
bioconjugates containing daunomycin for targeted therapy have been in the focus of intensive interest
since years [3–5]. The drug moiety, usually, is attached to a targeting peptide, which can bind specifically
to a receptor overexpressed in tumor cells, and the selective binding results in a specific antitumor
effect [6].
Tuftsin is a naturally occurring tetrapeptide (TKPR), a proteolytic fragment (289–292) of
the immunoglobulin G (IgG) Fc heavy chain [7]. Tuftsin derivatives have already been applied
in drug delivery systems using methotrexate as drug molecule [8,9]. Furthermore, the ε-amino group
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of the lysine provides a potential coupling site for the drug conjugation, and this branched structure
can increase the stability of the bioconjugates in biological systems, too [10,11].
Chemical synthesis of multicomponent bioconjugates is usually based on a complex chemical
strategy, in which mass spectrometry is a key technique for the fast and reliable identification of
the products. However, in the case of anthracyclines and anthracycline derivatives, it is difficult to
estimate the purity of the compounds due to the unusual fragmentation during MS analysis.
Electrospray ionization (ESI) and matrix-assisted laser desorption ionization (MALDI) are soft
ionization techniques, which usually produce intact protonated ions from peptides and proteins.
However, mass spectra of daunomycin containing bioconjugates show significant fragmentation
under the commonly used mass spectrometric conditions. Daunomycin itself usually produces
a characteristic in-source fragment ion pattern (Figure 1). The main fragmentation pathway is
the cleavage of the glycosidic bond, with the charge either residing on the aglycone or the daunosamine
part [12]; therefore, the sugar moiety can be cleaved (m/z 130.0), resulting in hydroxyl functionality
on the aglycone part (m/z 528.0 − 129.0 = 399.0) or eventuating in an unsaturated aglycone (m/z 528.0
− 147.0 = 381.0). Recently, an emerging number of research papers have been reported about
the synthesis of novel anthracycline-containing bioconjugates [13–17]. However, in most cases,
analytical data report complex mass spectra showing a mixture of protonated molecules, adduct ions,
and various fragment ions, and publications lack proper assignation and discussion of the detected
peaks. Therefore, homogeneity and structure of the compounds cannot be evaluated. We aimed to get
an insight into the impact of structural and instrumental features affecting spectrum quality and to






Figure 1. In-source fragmentation pattern of daunomycin (m/z 528.0, [M +H]+) under the commonly
used electrospray ionization-mass spectrometry (ESI-MS) conditions. The structures correspond to
the non-protonated molecules, and the protonation sites are not specified here.
Daunomycin can be linked to peptides either via the sugar moiety with an amide bond or via
the aglycon part with an oxime or hydrazone linkage. In the first case, the aglycon part [13], while in
the latter case, the sugar moiety [14–17] can be cleaved from the Dau-containing molecule during
the mass spectrometric analysis by in-source fragmentation, resulting in the above-mentioned complex
spectra. However, the glycosidic bond can be cleaved under acidic conditions during the synthesis of
the conjugate as well, and the loss of the daunosamine moiety leads to significantly decreased biological
effects [18]. Therefore, the use of reliable mass spectrometric techniques with significantly suppressed
in-source fragmentation processes is essential for the structural characterization of bioconjugates
and the differentiation of synthetic by-products from the planned molecule. This could also facilitate
the identification of other structural changes in the conjugates. A typical example is the O (aglycone)→
N (daunosamine) acyl transfer of doxorubicin-peptide conjugates with ester linkage, where the different
structures bear different biological effects while their molecular weight is the same. Therefore, it
is highly important to characterize the structure properly and clarify whether the drug molecule is
conjugated via an ester or an amide bond since the latter one is ineffective [19].
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Our research was focused on the detection of daunomycin-containing peptide conjugates
and the determination of appropriate circumstances for the mass spectrometric characterization of these
complex molecules. For this purpose, new tuftsin-based bioconjugates were synthesized to investigate
the gas-phase stability of Dau in the presence of positively charged amino acid residues (Figure 2).
The influence of structural elements on the fragmentation was studied in detail, including the (i)
number of drug molecules; (ii) number of basic functional groups; (iii) presence or absence of a widely
used enzyme-labile spacer (GFLG) between the targeting peptide and the drug molecule. We expected
that these structural modifications, i.e., the reduction of the number of charged functional groups
and the increased distance between the Dau and the peptide, would change the gas-phase stability
of daunomycin and the fragmentation could be different. Besides, our main goal was to suppress
the in-source sugar losses, and thereby to detect intact protonated molecules only. Therefore, we aimed




Figure 2. Schematic structure of the novel daunomycin-tuftsin bioconjugates.
2. Results
2.1. Synthesis of the Conjugates
All peptides were synthesized by solid-phase methodology using the Fmoc/tBu strategy.
Boc-protected aminooxyacetic acid (Boc-Aoa-OH) was coupled directly or through a short enzyme
labile spacer (GFLG) to the ε-amino group, that can be cleaved by the lysosomal enzyme cathepsin
B, resulting in different metabolite (Dau=Aoa-Gly-OH) in comparison with a direct attachment that
can serve H-Lys(Dau=Aoa)-OH metabolite after enzymatic decomposition. Dau was conjugated to
the purified aminooxyacetylated peptides by oxime linkage under slightly acidic conditions (pH 5.1).
The formed tuftsin-daunomycin bioconjugates and their dimer derivatives (containing two tuftsin units
and hereby two aminooxy groups and two Dau) were purified by reversed-phase high-performance
liquid chromatography (RP-HPLC). The purity of the products was analyzed by analytical HPLC
(analytical data, chromatograms in Supplementary Materials: Table S1 and Figures S1–S14).
2.2. Mass Spectrometric Analysis under the Commonly Used Conditions
The purified daunomycin-tuftsin conjugates were analyzed by ESI-MS (under the commonly
used conditions, from an acetonitrile/water solvent mixture containing 0.1% acetic acid or formic acid),
but the spectra showed several peaks. Among them, numerous peaks could be identified as fragment
ions and only less than 40% of the peaks as intact protonated ions. Especially bioconjugates containing
two daunomycin molecules (4, 5, 6) attached to the core peptide produced highly complex mass
spectra. These bioconjugates contained two glycosidic bonds that could split independently during
the mass spectrometric analysis, and the evaluation of the ESI-MS spectra was even more difficult due
to the combination of the sugar losses (Figure 3A). Hence, the overcharging of daunomycin-tuftsin
conjugates should be suppressed for unambiguous detection of the molecules and reliable analytical
characterization of the products.
According to our results, a free N-terminal amino group facilitated the cleavage of the glycosidic
bond, while blocking the N-terminal by formylation (2, 5), resulting in lower fragmentation, especially in
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the case of the monomer conjugate (2; Figure S3). Presence of the N-terminal formyl group was not
enough to eliminate the in-source split of the sugar moiety, but it could decrease this phenomenon
under the commonly used conditions. We also observed that the incorporation of a neutral spacer
(GFLG) between the peptide and the drug moiety (3, 6), hereby moving the sugar moiety away
from the peptide backbone and the functional group with basic character, could not only increase
the biological efficacy of the conjugates but also slightly decrease the in-source fragmentation during
ESI-MS (3; Figure S5, and 6; Figure S13). In the case of the monomer conjugate (1), a decrease of
the fragmentation due to the blocking of the N-terminal amino group (2) or due to the introduction of
the spacer moiety (3) resulted in simpler mass spectra with intact protonated molecules as base peaks.
 
Figure 3. ESI-MS spectra of conjugate 4 (A) under the commonly used ion source parameters (136 V
capillary exit potential); (B) using reduced capillary exit potential (5 V); (C) in non-acidic solvent
mixture (acetonitrile-water 50:50% v/v; 5 V capillary exit potential); (D) measured in 50 mM NH4OAc
buffer (pH = 6.7, diluted with acetonitrile 50:50% v/v; 5 V capillary exit potential). Blue circles are used
to label intact protonated molecules, yellow and red circles label protonated fragment ions with one
and two sugar losses, respectively. Charge states and m/z values of the protonated molecules are shown
in the Figure.
2.3. Mass Spectrometric Analysis under the Changed Conditions
Our main goal was to achieve the detection of intact protonated ions; therefore, the optimization of
the experimental conditions was performed to avoid overcharging and hereby inhibit the fragmentation
of the glycosidic bond. In our experiments, we focused on the suppression of the in-source fragmentation
phenomenon and investigated the effect of the capillary exit potential and the composition of the solvents
used for the ionization of the samples.
The results showed that a significant reduction of the capillary exit potential could slightly increase
the intensity of the intact protonated molecules. Use of the default capillary exit potential values
always resulted in high fragmentation levels implying fragment ions ([MW-1 sugar] and/or [MW-2
sugars]) as base peaks in the mass spectra (Figure 3A). However, fragment ions were still dominant for
conjugates containing a free N-terminal amino group (1, 3, 4, 6) using low capillary exit potential (5 V;
Figure 3B), while formylation of the N-terminal (2, 5) could significantly decrease the number of sugar
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losses, especially the simultaneous loss of two sugar moieties. It is important to note that other ion
source parameters did not affect the ion ratios significantly in the mass spectra.
Furthermore, we investigated the effect of using acidic vs. non-acidic solvent mixtures for ESI
ionization while keeping the reduced capillary exit potential. We used acetonitrile-water (50:50%, v/v)
mixture and solutions containing ammonium bicarbonate (NH4HCO3, 50 mM, pH 7.8) or ammonium
acetate buffers (NH4OAc, 50 mM, pH 6.7) and acetonitrile (50:50%, v/v). Our results showed that
the decrease in the number of charges on the protonated molecules formed during ESI ionization
reduced the spontaneous dissociation of the glycosidic bond (Figure 3D).
The non-acidic acetonitrile-water (50:50%, v/v) mixture could significantly decrease the amount
of the fragment ions in case of conjugates 1, 2, 3, and 5, while the elimination of the acid was not
effective for compounds 4 and 6, though the simultaneous loss of two sugar moieties was suppressed
(Figure 3C).
In case of the volatile buffers, intact protonated molecules of all bioconjugates were dominant.
NH4HCO3 buffer (50 mM, pH 7.8) was less effective, noisy spectra with lower intensities and only
~80% intact protonated ions were detected, while NH4OAc buffer (50 mM, pH 6.7) provided clearer
spectra and over 95% intact protonated ions.
Our results showed that the best quality spectra could be achieved with a combination of low
capillary exit potential (5 V) and the charge-reducing NH4OAc buffer (50 mM, pH 6.7). In this case,
only intact protonated molecules were found in the ESI-MS spectra of the bioconjugates.
3. Discussion
There is an increased interest in peptide-based small molecule drug conjugates (SMDCs) for
targeted tumor therapy. The most commonly used drugs in these constructs are anthracyclines; however,
their lability during mass spectrometric analysis leads to sugar loss and makes it difficult to estimate
the purity of the conjugates. The sugar loss is structure-dependent and can occur, especially in the case
of the most common positively charged peptide carriers like tuftsin derivatives or many cell-penetrating
peptides. Therefore, six new tuftsin-based daunomycin conjugates were prepared where Dau was
linked to the aminooxyacetyl modified peptides via oxime linkage (Figure 2). Conjugates 1, 2, and 3
contained one tuftsin and one Dau molecule, while conjugates 4, 5, and 6 were their linear dimer
derivatives with two tuftsin units and two Dau (Figure 2). Using N-terminal formylation (conjugates 2
and 5; Figure 2B), the number of free amino groups was reduced. Furthermore, the incorporation of
a peptide spacer (GFLG) between the targeting peptide and the drug molecule (conjugates 3 and 6;
Figure 2C) increased the distance between the positively charged amino acids and the daunomycin.
This cathepsin B labile spacer can be cleaved in the lysosomes and increase the efficacy of the drug
release [20], while it can change the analytical features, too.
In the ESI-MS spectra of the daunomycin-tuftsin conjugates, intact protonated ions are present in
very low intensities only (<40%), which is an unusual feature in the ESI spectra of peptides, and it is
a strong bottleneck of further mass spectrometry-based structural or analytical studies. Unfortunately,
chemical degradation may also occur during the synthesis or the storage of these conjugates [13]. We also
observed the cleavage of the sugar moieties in some conjugates after the RP-HPLC purification. This
side reaction led to biologically less active by-products while having identical m/z values to the fragment
ions (Figures S5 and S7); therefore, these species could not be differentiated under the commonly used
MS conditions, and the purity of the compound could not be verified. Therefore, the development of
appropriate conditions for efficient MS analysis is necessary.
We observed that the high number of charges on the peptide moiety induced a spontaneous
dissociation of the glycosidic bond because of the repulsion of the positive charges. This phenomenon
can be explained with the solvated proton theory. After ionization, H+ ions are localized on the most
basic sites of the molecule, e.g., on the N-terminal and the side chain of basic amino acid (arginine, lysine,
and histidine) residues. The population of different protonated forms depends on the internal energy
content of the peptide and the gas-phase basicities of the different protonation sites. If an amino acid side
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chain (e.g., arginine) tightly binds a proton, then it can be solvated by other heteroatoms in the system.
Location of the charge and the intramolecular hydrogen bonds can directly influence the structure
and stability of the gas-phase ion [21,22]. The number and location of charges determine the extent of
stability of the formed ions, and the too-high charge-repulsion can cause spontaneous fragmentation.
Interesting examples are oligotuftsin peptides (repeating Thr-Lys-Pro-Arg peptide units [7]) since these
peptides bear numerous protonation sites and produce ions with particularly high charge states using
ESI-MS, hereby fragmentation can already occur in a single stage MS experiment due to charge repulsion.
This phenomenon is defined here as “overcharging” or “overprotonation” of the analyte. We apply this
term for cases, in which the high number of charges (protons) cause difficulties in a mass spectrometric
experiment, especially due to the spontaneous dissociation of the analyte. From a practical point
of view, overcharging is the opposite of supercharging. Supercharging is used for techniques, in
which the number of charges is increased artificially. It is usually achieved by adding a supercharging
reagent to the electrospray solution that increases the average charge of peptides and proteins. This
facilitates high-resolution MS by reducing mass-to-charge (m/z) ratios and, therefore, improves peptide
and protein identification in proteomics applications [23–28]. In the case of overcharging, the number
of charges needs to be decreased artificially to obtain an ESI-MS spectrum with appropriate quality.
Numerous methods for reducing the number of charges has been developed in the last few years.
Ion/ion gas-phase reactions [29], 210Po α-particle source-based charge reduction [30,31], and interface
acid vapor leak-in [32] have already been used successfully for multiply-charged proteins. Charge
reduction can also be achieved by using basic buffer salts, such as ammonium acetate, or solution
additives with strong gas-phase basicities that can decrease the acidification during ionization [33].
The novel daunomycin-tuftsin conjugates behaved as expected under the commonly used
conditions, i.e., a higher number of positively charged functional groups in the molecule indicated
higher fragmentation. Consequently, intact protonated ions were detected in lower amounts in
the case of the free N-terminal containing conjugates, while formylation of the N-terminal (2 and 5)
resulted in significantly lower fragmentation. We also found that enhanced distance between
the sugar moiety and the positively charged peptide backbone (incorporation of the GFLG spacer)
decreased the fragmentation. According to these observations, we can conclude that special structural
modifications can influence (enhance or decrease) the gas-phase stability of daunomycin, i.e., affect
the split of the sugar moiety, but these effects are rather small. An overview of these data is represented
in Figure 4.
We hypothesized that optimized ion source parameters or appropriate solvent mixtures used
for the ionization would reduce the in-source fragmentation of the samples. Hence, we changed
the capillary exit potential, and we could show that the reduction of this mass spectrometric parameter
could slightly decrease the fragmentation. In the case of compound 2, this modification in the mass
spectrometric conditions resulted in a significantly improved spectrum, in which intact protonated
ions were detected as base peaks (97%, Figure 4). The spontaneous dissociation of the glycosidic
bond was facilitated by the highly charged peptide chain, therefore, shifting the charge states to lower
charges could help to keep ions intact during ESI-MS analysis. Hence, application of neutral or slightly
basic volatile buffers for the ESI-MS measurements could significantly reduce the fragmentation of
the analyte and, therefore, reduce the amount of the sugar lost ions in the spectra. In our experiments,
the most appropriate buffer for suppressed fragmentation was ammonium acetate (pH 6.7). NH4OAc
buffer in acetonitrile combined with low capillary exit potential (5 V) could significantly reduce
the charge states of various daunomycin-tuftsin conjugates and decrease their in-source fragmentation
(Figure 4).
In conclusion, not only the settings of the mass spectrometer but also the structure of
the daunomycin-tuftsin conjugates had a high impact on the ESI-MS spectra. Though structural
changes can assist the reduction of the fragmentation, overprotonation can only be suppressed with
appropriate solvents and optimized mass spectrometric settings. These conditions can be useful in
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the analysis of anthracycline-containing bioconjugates in general, to obtain mass spectra comprising
intact protonated molecules only.
 
α
Figure 4. The intensity of the intact protonated ions (%) in the case of novel tuftsin-daunomycin
conjugates under various conditions. The capillary exit potential, the solvents, and the pH were
modified systematically.
4. Materials and Methods
4.1. Chemicals
All amino acid derivatives, the Wang resin, N,N’-diisopropylcarbodiimide (DIC), and trifluoroacetic
acid (TFA) were purchased from Iris Biotech GmbH (Marktredwitz, Germany). Boc-aminooxyacetic
acid (Boc-Aoa-OH), 1-hydroxybenzotriazole hydrate (HOBt), 4-(dimethylamino)pyridin (DMAP),
triisopropylsilane (TIS), and hydrazine hydrate were obtained from Sigma Aldrich Kft.
(Budapest, Hungary). Aminooxyacetic acid, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) were from
TCI Europe N.V. (Zwijndrecht, Belgium), while piperidine was purchased from Molar Chemicals
Kft (Budapest, Hungary). Formic acid 2,4,6-trichlorophenyl ester (For-OTcp) was prepared in our
laboratory from formic acid and 2,4,6-trichlorophenol with N,N′-dicyclohexylcarbodiimide (DCC)
(Sigma Aldrich Kft. Budapest, Hungary). Daunomycin hydrochloride was a kind gift from IVAX
(Budapest, Hungary). All solvents used for synthesis and purification were purchased from VWR
International Kft. (Debrecen, Hungary).
Solvents and salts (NH4OAc, NH4HCO3) for the mass spectrometric measurements were
purchased from Sigma Aldrich Kft. (Budapest, Hungary). Double distilled water was used for
sample preparation.
All reagents and solvents were of analytical grade or highest available purity.
4.2. Preparation of Daunomycin-Peptide Bioconjugates
The peptides were synthesized manually by solid-phase peptide synthesis using the Fmoc/tBu
strategy on Wang resin (0.6 mmol/g capacity) in a funnel equipped with a filter. The first amino acid
(Fmoc-Arg(Pbf)-OH, 2 equiv. to the resin capacity) was coupled using an equivalent amount of DIC
in N,N-dimethylformamide (DMF) in the presence of 0.1 equiv. DMAP to the amino acid derivative.
All other amino acids were coupled with DIC/HOBt (3 equiv. each to the resin capacity) in DMF. Fmoc
group was cleaved with 2% piperidine + 2% DBU in DMF in four steps (2+2+5+10 min). Peptides
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with free N-terminus were synthesized using Boc-Thr(tBu)-OH as the last amino acid of the peptide
backbone. The N-terminal of formylated derivatives was reacted with 2,4,6-trichlorophenyl formate.
Then, the lysine side chain protecting group (Dde) was selectively cleaved with 2% hydrazine hydrate
in DMF on resin, and Boc-protected aminooxyacetic acid was coupled either directly to the ε-amino
group of the lysine or to a GFLG spacer that was built up earlier on the lysine side chain with
the standard Fmoc/tBu protocol. Peptides were cleaved from the resin (and all protecting groups were
also removed) with 95% trifluoroacetic acid, 2.5% water, 2.5% TIS (v/v/v) in the presence of 10 equiv.
free aminooxyacetic acid as “carbonyl capture” reagent [16] for 30 min at 0 ◦C, then 2 h at room
temperature followed by precipitation with ice-cold diethyl ether, washing three times with diethyl
ether and solubilization in distilled water for freeze-drying. The crude peptides were purified by
RP-HPLC, and the pure fractions were immediately used for the next synthetic step after evaporation
of the solvent. Daunomycin was conjugated to the peptides in solution (0.2 M NH4OAc, pH 5.1)
at a peptide concentration of 10 mg/mL. The reaction mixtures were stirred at room temperature
for 16 h, and the resulting bioconjugates were purified by RP-HPLC. The purity of the conjugates was
investigated by analytical HPLC using a Knauer HPLC system and a Nucleosil C18 column (5 µm,
100 Å; 250 × 4.6 mm). Eluents were 0.1% TFA in water (A) and 0.1% TFA in acetonitrile-water 80:20%,
v/v (B). All chromatographic separations were performed at room temperature.
4.3. Mass Spectrometry
Mass spectrometric experiments were performed by electrospray ionization on a Bruker Daltonics
Esquire 3000+ (Bruker Daltonic GmbH, Bremen, Germany) ion trap mass spectrometer, operating
with continuous sample injection at 10 µL/min flow rate. Mass spectra were recorded in positive
ion mode in the m/z 50–2000 range, with 250 ◦C heating and N2 as nebulizer (10 psi) and dry gas
(4 L/min). Stock solutions were prepared in double-distilled water (cstock = 1 nmol/µL) and diluted
with the solvent mixtures. Samples were analyzed in acetonitrile-water (50:50%, v/v) mixture with
or without 0.1% acetic acid (cconj.;acidic = 10 pmol/µL and cconj.;non-acidic = 20 pmol/µL) and solutions
containing NH4HCO3 (pH 7.8) or NH4OAc buffers (pH 6.7) and acetonitrile (50:50%, v/v, final buffer
concentration was 50 mM; cconj.;buffer = 50 pmol/µL).
Supplementary Materials: The following are available online, Table S1: Characteristics of daunomycin-tuftsin
conjugates, Figure S1: ESI-MS spectra of 1, Figure S2: Analytical HPLC chromatogram of 1, Figure S3: ESI-MS
spectra of 2, Figure S4: Analytical HPLC chromatogram of 2, Figure S5: ESI-MS spectra of 3, Figure S6: Analytical
HPLC chromatogram of 3, Figure S7: ESI-MS spectrum of sugar-lost, purified 3, Figure S8: Analytical HPLC
chromatogram of sugar-lost 3, Figure S9: ESI-MS spectra of 4, Figure S10: Analytical HPLC chromatogram of 4,
Figure S11: ESI-MS spectra of 5, Figure S12: Analytical HPLC chromatogram of 5, Figure S13: ESI-MS spectra of 6,
Figure S14: Analytical HPLC chromatogram of 6.
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activity of novel drug delivery systems containing tuftsin derivatives and methotrexate. Bioconjug. Chem.
2008, 19, 2260–2269. [CrossRef]
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